

INDEX

Note: Page numbers in *italics* indicate figures.
Page numbers followed by a “t” indicate tables.

I-2-3 Magic: Effective Discipline for Children (Phelan), 100t

Academic performance, 20, 33-35

Accommodations, academic or employment, 54-55, 105-106, 109

ADD (attention-deficit disorder), 12

with or without hyperactivity (*DSM-III*), 11, 12

organizations and web sites, 56

ADD Warehouse, 56

ADDA (web site), 56

Adderall, Adderall XR, 66t, 81. See also *Amphetamines*.

cardiac side effects and, 78-79

duration of action, 80, 81

efficacy and safety, 81, 82

Additives, food, 111-112

ADHD (attention-deficit/hyperactivity disorder)

controversy about, 13

core symptoms, 24t

destigmatizing, 49, 55-56

etiology of, 15-16

history of, 9-12, 11

impact of, 9, 20-21

introduction to, 9-14

long-term outcomes, 20-21

myths about (and corrections), 9-12

prevalence of, 12, 16-20, 18, 119

school services for, 105-107

“subsyndromal,” 29-30

subtypes, 11, 12, 23, 24t, 27-28

support/advocacy groups, 56

timeline, 11

Adolescents

behavioral interventions for, 107-109

brain development in, 50, 62

communication with, 107

comorbid conditions in, 62

conduct disorder and, 121

diagnosis in, 24-25, 28-29

algorithm for, 25

difficulties of, 62

driving (motor vehicle), 52, 94, 125, 126t

feedback for, 47-49, 107

medications, 124-125. See also *Medications for ADHD*.

algorithm for, 93

coverage needs, 94

diversion of, 94, 125-128, 128t

Adolescents, medications (*continued*)

duration of action, 77

efficacy, 62, 81, 82

response rate, 60

positive reinforcement for, 107

prevalence of ADHD in, 119

rating scales for, 30-31, 30t, 32t

risk-taking behaviors, 52, 122

substance-use/abuse disorders and, 119-122, 125-127

screening for, 122-124, 123

symptoms in

change with age, 30

continuing into adulthood, 9, 12, 30

core, 24t

transition to adulthood, 50-55

driving, 52

planning for independence, 52-55, 53t

post-high school years, 53-55, 53t

risk-taking behaviors, 52, 122

treatment/management plan for, 50-55, 53t

participation in, 50-51, 62

Adults

behavioral interventions for, 107-109

comorbidities in, 56, 62

diagnosis in, 16, 24-26, 26, 28-29

management plan for, 55-57

medications. See also *Medications for ADHD*.

algorithm for, 93

benefit of, 12, 13

duration of action, 77

lisdexamfetamine approval/efficacy for, 83-86, 84-85, 87

nonstimulant, 86-88

OROS-MPH approval/efficacy for, 72, 73

response rate, 60

prevalence rate in, 19

rating scales for, 31-32, 32t

substance-use disorders in, 120-122

symptoms in, 9, 12, 20, 30

Wechsler Adult Intelligence Scale (WAIS), 34

Advocacy groups, 56

Affective disorder, 56

African Americans

ADHD diagnosis in, 20

ADHD prevalence in, 19

ADHD treatment efficacy in, 20

Age

ADHD symptoms and, 9, 12

stimulant medications and, 60-61, 91

- Agitation
 bupropion and, 90
 manic/depressive episodes and, 38t
 withdrawal from substance use and, 124
- Alcohol
 abuse/dependence, 119, 120, 121
 fetal exposure to, 15, 41
- Algorithms for diagnosis
 of ADHD in adults, 26
 of ADHD in children/adolescents, 27
 of substance abuse, 123
- α -Adrenergic medications, 89-90
- Alternative treatments for ADHD
 alternative medications, 114-115
 communicating with patient about, 116
 dietary supplements, 113-114
 diets, 111-113
 exercises and training, 115-116
- American Academy of Child and Adolescent Psychiatry (AACAP), 79
- American Academy of Pediatrics (AAP)
 guidelines for diagnosis, 23-24
 recommendation on ECGs, 79
- American Heart Association (AHA) recommendations, 78-79
- Americans With Disabilities Act, 54, 109
- Amphetamine salts, mixed, 66t, 81
 efficacy, 81, 82
 vs lisdexamfetamine, 83, 84-85
- Amphetamines, 66t, 79-86. See also *specific amphetamines*.
 dextroamphetamine, 66t, 79-80
 dosing, 66t, 91
 duration of action, 79, 80, 80
 lisdexamfetamine, 66t, 81-86
 in medication algorithm, 93
 mixed amphetamine salts, 66t, 81
 prodrug (lisdexamfetamine), 81-83
 selection of, 91
 side effects, 79-80, 81
- Anorexia. See also *Appetite suppression*.
 α -adrenergic medications and, 90
 bupropion and, 90
 mixed amphetamine salts and, 81
 tricyclic antidepressants and, 89
- Antibiotics, 114
- Anticholinergic effects, tricyclic antidepressants and, 89
- Antidepressants, tricyclic, 59, 89
- Antifungal agents, 114-115
- Antioxidants, 114
- Antisocial personality disorder, 36, 127
- Anxiety disorders, 28, 32-33, 39, 56, 62
- Apnea, sleep, 32
- Appetite suppression. See also *Anorexia*.
 amphetamines and, 80, 81
 atomoxetine and, 86
 lisdexamfetamine and, 86
 methylphenidate and, 75
 modafinil and, 91
- Armed services, career in, 55
- Arrhythmias, cardiac, 56, 78
 tricyclic antidepressants and, 89
- Assessment. See *Diagnosis; Rating scales*.
- Atomoxetine (Strattera), 86-88, 94
 efficacy, 86, 88
 as first drug of choice, 94
 half-life, 86
 in medication algorithm, 93
 in substance-use disorders, 126t
- Attention-deficit disorder (ADD), 11, 12, 56
- Attention-deficit/hyperactivity disorder. See *ADHD*.
- Auditory training, 116
- Autism, 28, 32
- Ayres, Jean, 115
- Barkley rating scale, 31
- Behavior-modification training, 99-105
 books and web resources, 100t
 principle elements of, 104t
 programs in, 101t-103t
- Behavioral Assessment System for Children, 2nd Edition (BASC-2), 35
- Behavioral disorders, other than ADHD, 35-40
- Behavioral interventions, 89, 99-105
 for adolescents and adults, 107-109
 for pre-school children, 62, 92, 99
- Benzedrine, 11, 59
- Biofeedback, 115
- Bipolar disorder, 32-33, 36-38, 38t, 62
 substance-use disorders and, 121
- Birth, premature, 15
- Birth trauma, 15
- Blood pressure, monitoring, 79, 92
- Bradley, C., 11, 59
- Brain
 anatomy, 15-16
 development, 50, 61, 62
 imaging, 16
- Brain damage
 ADHD and, 10-12, 15-16
 minimal cerebral (MBD), 10-12, 11, 13
- Brown, Tom, 32
- Brown Adult ADD Scale, 32t

Brown Adults Attention Disorder Scale (BAADS), 32
Bupropion (Wellbutrin), 90, 126t

CAARS (Conners Adult ADHD Rating Scale), 31
Candida, 114

Cannabis use/abuse, 119, 121
Cardiac arrhythmias, 56, 78, 89
Cardiac history and evaluation, 78-79
Cardiac side effects, 78-79, 128t
Cars/driving. See *Driving*.
Catapres (clonidine), 89-90
CD. See *Conduct disorder*.

Center for Effective Parenting, 100t
Centers for Disease Control (CDC) study, 19
Central nervous system (CNS). See also *Brain*.
disorders, ruling out in diagnosis, 32
mechanisms in ADHD, 15-16

Cerebral metabolic enhancing agents, 115
Cerebral palsy, 32

CHADD (Children and Adults with ADHD), 56, 100, 100t
parenting program, 101t-103t
Chamomile, 114

Child and Family WebGuide, 100t
Child Behavior Checklist (CBCL), 35
Childhood schizophrenia, 28

Children

behavioral interventions for, 62, 92, 99-105
bipolar disorder symptoms in, 37-38
brain development in, 61
core symptoms, 24t
continuing into adulthood, 9, 12, 30
monitoring, 91-94
daily report card (DRC), 107, 108t
diagnosis in, 16, 23-25, 25
diets for ADHD, 111-112
feedback for, 47-49, 107, 108t
growth potential/height, 61, 76
Incredible Years (IY) training, 101t
management plan for, 45-49, 46t, 48
medications for. See also *Medications for ADHD*.
age and, 60-61, 91
algorithms for, 92, 93
dosing, 91
nonstimulant medications, 86
response rates, 60-61, 61
safety concerns and recommendations, 61-62, 78-79
stimulant medications, 35, 60-61, 83
other behavioral disorders, 35-40
parent-training programs and, 99-105, 100t, 101t-103t
positive attention and reinforcement for, 103-105, 104t

Children (*continued*)

prevalence of substance use disorders, 119
rating scales for, 30-31, 30t
sudden cardiac death in, 78, 79
Wechsler Intelligence Scale for (WISC-IV), 34
Children and Adults with ADHD (CHADD), 56, 100, 100t
parenting program, 101t-103t
Children's Depression Inventory, 35
Chronic-illness model for ADHD, 45-57, 46t
Cigarettes. See *Nicotine exposure*.
Clinical information systems, 46, 46t
Clinical interview, 25, 26
Clonidine (Catapres), 89-90
Closed head injuries, 32, 41
CNS. See *Central nervous system*.
Coaching, 99, 107-109
Cocaine use, 120, 121
Cognitive impairments, 32, 33-35
Cognitive therapies, 99
College
medication coverage needs during, 94
medication diversion and, 94, 125-127, 128t
planning for students with ADHD, 53-55, 53t
Communication, 47-49, 57, 107
about alternative therapies, 116
about confidentiality, 51
daily report card, 107, 108t
destigmatizing ADHD, 49, 55-56
Community resources, 45-46, 46t, 57
Comorbid conditions, 32, 33-41, 56, 62. See also *Substance-use disorders*.
externalizing conditions, 35-36, 36t
internalizing conditions, 36-40, 38t
learning and language disorders, 33-35
motor disorders/physical conditions, 40-41
other behavioral disorders, 35-40
prevalence in ADHD, 33
Concerta. See *OROS-methylphenidate*.
Conduct disorder (CD), 35-36, 37t
substance-use disorders and, 36, 120, 121
Confidentiality, provider communication about, 51
Conners Rating Scales, 30, 30t, 31
Adolescent ADD Scale, 32t
Adolescent ADHD scale, 31
Adult ADD Scale, 32t
Adult ADHD Rating Scale (CAARS), 31
specific medication assessments with
methylphenidate CD, 69-70, 70
mixed amphetamine salts, 81, 82
Ritalin LA, 70-71, 71

Conners Rating Scales (*continued*)

Teacher and Parent Rating Scales, Revised, 30, 30t, 35
Consultants, 46, 47
Controversies about ADHD, 13
Coordination deficits, 31
Coronary heart disease, 56
Counseling, 107-109
for substance abuse, 125, 126t
Criminal justice department, career in, 55
Cultural differences, 27t
Cytochrome P-450 2D6 pathway, 86

D4 receptor gene (DRD4), 15

Daily report card (DRC), 107, 108t

Daytrana (methylphenidate transdermal patch), 66t

abuse potential, reduced, 64

dosing, 66t, 91

duration of action, 77

Death, thoughts of

atomoxetine and, 86

major depression and, 38t

Decision support, 46, 46t

Depression, 32-33, 36-39, 38t, 62

bipolar disorder and, 36-38, 38t

major depressive episode, 36-37, 38t

Desipramine (Norpramin), 89

Destigmatizing ADHD, 49, 55-56

Developmental coordination disorder (DCD), 31, 40-41

Developmental disorders, pervasive, 28, 32

Developmental level, diagnosis and, 23, 28

Dexamphetamine. See *Dextroamphetamine*.

Dexedrine, Dexedrine Spansule, 66t. See also *Dextroamphetamine*.

Dexmethylphenidate (Focalin, Focalin XR), 66t, 73-74

dosing and pharmacokinetics, 66t, 77

duration of action, 77

efficacy, 73-74, 74

Dextroamphetamine (Dexedrine, Dexedrine Spansule, Dextrostat),

59, 66t

dosing and pharmacokinetics, 66t, 80

duration of action, 79, 80, 80

efficacy, 60

half-life, 79

safety, 63, 80

side effects, 79-80

vs methylphenidate, 65, 67t, 68t

Dextrostat, 66t. See also *Dextroamphetamine*.

Diagnosis of ADHD, 13, 23-43

AAP guidelines, 23-24

in adults, 16, 24-27, 26, 28-29

algorithm for, 26

Diagnosis of ADHD (*continued*)

challenges/difficulties in, 16, 17-18, 28-33, 122-124

in children, 16, 23-25

algorithm for, 25

clinical interview, 16, 25, 26, 32-33

comorbid conditions, 33-41

externalizing conditions, 35-36, 36t

internalizing conditions, 36-40, 38t

learning/language disorders, 33-35

motor disorders/physical conditions, 40-41

other behavioral disorders, 35-40

substance-use disorders, 122-124, 123

continuum and context of behaviors in, 29

criteria, 23, 24t

age and, 27t, 28

changes in, 18

core symptoms, 24t, 29

DSM criteria, 11, 12, 18, 23, 28

functional impairment, importance of, 28, 31

hyperactivity/impulsivity dimension, 24t

inattention dimension, 24t

normative, lack of, 17

other criteria, 27-28

persistence of symptoms, 27t, 28

developmental level and, 23, 28

differential diagnosis, 28, 31, 32-33

history in, 32-33

individual variability and, 16

misdiagnosis/underdiagnosis, 19-20

neurologic exam, 25, 26

other medical conditions and, 28

physical exam, 25, 26, 32

rating scales, 30-32, 30t, 91-92, 134-145

sources of information, 23-27, 27t

for adults, 25-26, 92

for children, 23-25

disagreements in, 26-27, 27t, 29

other than parents and teachers, 27t, 29

parents, 23-27

self reports, 16

subjectivness in, 16, 17-18

teachers, 23-27, 29

“subsyndromal” patients, 29-30

tests and assessments, 30-32

Diagnostic and Statistical Manual of Mental Disorders. See *DSM*.

Dietary supplements, 113-114

Diets for ADHD, 111-113

Feingold diet, 111-112

oligoantigenic (oligoallergenic, Few-Foods) diet, 112

sugar-restriction diet, 112-113

- Dimethylaminoethanol, 115
- Discipline/punishment, in behavior-modification training, 103, 104t, 105
- Dopamine neurotransmitter systems, 16, 63
- Dopamine transporter gene (DAT1), 15
- Driving (motor vehicle), 52, 94
accidents/violations, 20, 52, 120
advice and cautions about, 125, 126t
- Drug abuse/dependence. *See Substance-use disorders.*
- Dry mouth
 α -adrenergic medications and, 90
lisdexamfetamine and, 86
- DSM* (Diagnostic and Statistical Manual of Mental Disorders), *II*, 12
ADHD criteria in different versions, *II*, 12, 18, 23, 24t, 28
ADHD prevalence rates and, 18, 18, 19
comorbidity definition, 33
depressive/manic episodes, criteria for, 38t
DSM-IV
ADHD criteria in, *II*, 12, 23, 24t, 28
ADHD prevalence rates and, 18, 18
DSM for Primary Care Child and Adolescent Version, 29
rating scales, 30-32, 30t, 32t
substance abuse/dependence criteria, 126t-127t
“subsyndromal” behaviors, 29
- DuPaul Parent and Teacher Rating Scales, 30, 30t
- Dyes, food, 111-112
- Dyslexia, 33
- ECGs (electrocardiograms)
stimulant medications and, 79, 81
tricyclic antidepressants and, 89
- Education
accommodations in, 54-55, 105-106, 109
on ADHD, for patients and family, 47, 49, 55-56
individual education plan (IEP), 106
mainstreaming in, 106
- EEG biofeedback, 115
- Electrocardiograms (ECG), 79, 81, 89
- Electroencephalogram (EEG), 31
- Employment
accommodations in, 54-55, 105-106, 109
career choices, 54-55
- Encephalitis, influenza, 10
- Essential fatty acids (EFAs), 113
- Etiology of ADHD, 15-16
- Evidence-based Psychotherapies for Children and Adolescents*
(Kazdin and Weisz, eds.), 100t
- Executive function, 30, 122
- Exercises and training, 115-116
- Externalizing conditions, 35-36, 36t
- Facts for Families, 57
- Family. *See also Parents.*
education for, 47, 49
involvement in ADHD management, 45, 46-47
- Family history
of ADHD, 15, 55
of bipolar disorder, 36-37
- Family therapy, 99
- Fatigue
 α -adrenergic medications and, 90
major depression and, 38t
- FDA-approved medications, 59-88, 66t.
See also Medications for ADHD.
- Feedback
EEG biofeedback, 115
for patients (on ADHD treatment/progress), 46, 47-49, 107, 108t
- Feingold diet, 111-112
- Females, ADHD prevalence in, 12, 19
- Fetal alcohol syndrome, 15, 41
- Few-Foods diet, 112
- Fire department, career in, 55
- Focalin, Focalin XR. *See Dexamethylphenidate.*
- Food additives, preservatives, and dyes, 111-112
- Fragile X syndrome, 32, 41
- Functional magnetic resonance imaging (fMRI), 16
- Gender, ADHD prevalence and, 12, 19
- Generalized anxiety disorder (GAD), 39
- Genetic diseases mimicking ADHD symptoms, 32
- Genetic factors in ADHD, 15, 55
- GI constrictures, 71
- Ginkgo biloba, 114
- Growth potential (height), 61, 76
- Guanfacine (Tenex), 89-90
- Head injuries, 32, 41
- Headache
amphetamines and, 81
history of, 75-76
methylphenidate and, 75-76
modafinil and, 91
- Health care organizations, 45-46, 46t
- Health questionnaires. *See Rating scales.*
- Heart (cardiac) side effects, 78-79, 128t
- Heart disorders
congenital, 78
family history of, 78
- Height, 61, 76
monitoring, 61, 92
- Helping the Noncompliant Child* (Forehand and McMahon), 101t

- Hepatotoxicity, atomoxetine and, 86
- Herbal compounds, 114
- Heritability, ADHD and, 15, 55
- History of ADHD, 9-12
- Hoffman, Heinrich, 9
- Hyperactive child syndrome, *II*, 12
- Hyperactivity
 - criterion in ADHD diagnosis, 23, 24t, 27t
 - persistence into adulthood, 20
 - predominantly hyperactive/impulsive subtype of ADHD, 12, 24t, 28
 - as secondary deficit in ADHD, 12
 - “subsyndromal,” 29
 - withdrawal from substance use and, 124
- Hypertension, 56, 78
- Hypotension, 90
- IDEA (Individuals with Disability Education Act), 105-106
- IEP (individual education plan), 106
- Imipramine (Tofranil), 89
- Impulsivity
 - criterion in ADHD diagnosis, 23, 24t
 - withdrawal from substance use and, 124
- Inattention
 - criterion in ADHD diagnosis, 23, 24t
 - predominantly inattentive subtype of ADHD, 12, 19, 24t, 27
 - as primary deficit in ADHD, 12
 - “subsyndromal,” 29
 - withdrawal from substance use and, 124
- Incredible Years (IY)* training, 101t
- Individual education plan (IEP), 106
- Individuals with Disability Education Act (IDEA), 105-106
- Infections, ADHD and, 10, 15
- Influenza epidemic (1917-1818), 10, *II*
- Inheritance, ADHD and, 15, 55
- Insomnia
 - amphetamines and, 81, 86
 - bupropion and, 90
 - major depression and, 38t
 - modafinil and, 91
- Intelligence
 - communication about, 49, 55-56
 - standardized tests of, 34
- Internalizing conditions, 36-40
- Johnny Look-in-the-Air* (Hoffman), 9-10
- Kava hops, 114
- Ketoconazole, 114
- Klinefelter’s syndrome, 32
- Language assessment, 105-106
- Language disorders, 33-35
- Lead exposure, 15, 31, 32
- Learning and language disorders, 32, 33-35, 122
 - substance use disorder and, 122
- Learning disabilities, 28, 94
- Lemon balm, 114
- Linoleic/linolenic acids, 113
- Lisdexamfetamine (Vyvanse), 66t, 81-86. See also *Amphetamines*.
 - abuse potential, reduced, 64, 81-83, 128
 - dose, 64, 66t, 91
 - duration of action, 80, 83
 - efficacy, 83-86, 84-85, 87
 - as prodrug, 81-83
 - side effects, 86
 - tolerability, 86
 - vs mixed amphetamine salts, 83, 84-85
- Listlessness, stimulant medications and, 76
- Long-term outcomes of ADHD, 20-21
- Magnetic resonance imaging (MRI), 16, 31
- Mainstreaming, in schools, 106
- Males, ADHD prevalence in, 12, 19
- Management plan for ADHD, 46-49, 48.
 - See also *Treatment of ADHD*.
 - for adolescents, 50-55, 53t, 62
 - for adults, 55-57
 - behavioral interventions in, 99-110
 - form for, 48
 - goals in, 47
 - patient/family involvement in, 45, 46-47, 62
 - self-management support, 45, 46-47, 46t
- Manic episodes, 36-37, 38t
- Marijuana use/abuse, 119, 121
- Marital relations, 20, 56
- MBD. See *Minimal cerebral brain dysfunction/damage*.
- Medications for ADHD, 59-97. See also *specific medications*.
 - abuse potential, lower, 64, 81-83, 128
 - for adults, 12, 13
 - algorithms
 - for preschool-age, 92
 - for primary school through adult, 93
 - alternative, 114-115
 - career choice and, 55
 - for comorbid conditions, timing of, 63
 - consent of patient and, 50
 - coverage needs, 94
 - diversion of, 94, 125-128
 - guidelines for avoidance and recognition of, 127-128, 128t
 - red flags and precautions for, 128t

Medications for ADHD (*continued*)
 efficacy, 13, 60-63
 FDA-approved, 59-88, 66t
 individual differences in response to, 74-75, 76, 80, 91
 management of, 91-95
 monitoring of, 91-94
 non-FDA-approved, 88-91
 α-adrenergic medications, 89-90
 bupropion, 90
 modafinil, 90-91
 tricyclic antidepressants, 89
 nonstimulant medications (atomoxetine), 86-88, 88
 selection of, 64, 91
 stimulant medications, 59-88, 66t
 age and, 60-61
 amphetamines, 66t, 79-86
 blood concentration over time, 59, 60
 cardiac side effects, 78-79
 choice of, 64, 91
 differences in, 63
 dosing and pharmacokinetics, 66t, 76-78, 77, 91
 efficacy, 60-63, 61
 history of, 59
 lisdexamfetamine, 66t, 81-86
 methylphenidate, 65-79, 66t
 misconceptions, 63-64
 response rates, 60-61, 61
 safety, 61-62, 63
 substance-use disorders and, 126t-127t
 titration, 64-65, 91
 substance abuse concerns and, 119
 in substance-use disorders, 126t-127t
 titration of, 64-65, 91, 92
 Megavitamins, 113
 Melatonin, 114
 Meningitis, 15
 Mental health specialists
 links with, 46, 47
 referral to, 92, 93
 Mental retardation, 34
 Metadate CD (methylphenidate), 66t, 69-70.
 See also *Methylphenidate*.
 dosing and pharmacokinetics, 66t, 77
 duration of action, 77
 efficacy, 69-70, 70
 Methylin, Methylin ER (methylphenidate), 66t.
 See also *Methylphenidate*.
 Methylphenidate (MPH), 11, 65-79, 66t
 blood concentration over time, 60
 blood count, monitoring, 78

Methylphenidate (MPH) (*continued*)
 contraindications, 71
 controversy about, 13
 dosing and pharmacokinetics, 64, 66t, 76-77, 91
 dose response, 61
 duration of action, 65, 69, 77-78, 77
 Metadate CD, 69
 OROS-MPH (Concerta), 71
 Ritalin SR, 69
 transdermal patch (Daytrana), 74-75
 efficacy, 60-63, 61, 65-75
 dexmethylphenidate (Focalin), 73-74, 74
 Metadate CD, 69-70, 70
 methylphenidate patch (Daytrana), 74-75, 75
 OROS-MPH (Concerta), 71-72, 72, 73
 Ritalin LA, 70-71, 71
 formulations, 65, 66t, 76-77
 with lower abuse potential, 64
 microbead technology, 69, 71, 73
 osmotic pump, 71
 transdermal patch, 64, 66t, 74-75
 half-life, 65
 in medication algorithms, 92, 93
 response rates/response to second medication, 65-69, 67t, 68t
 safety profiles, 63
 seizures and, 63
 selection of, 91
 side effects, 75-76
 cardiac, 78-79
 vs dexamphetamine, 65, 67t, 68t
 Microbead technology, 69, 71, 73
 Minimal cerebral brain dysfunction/damage (MBD), 10-12, 11, 13
 Mixed amphetamine salts. See *Amphetamine salts, mixed*.
 Modafinil (Provigil), 90-91
 Molds, antifungal agents for, 114-115
 Mood disorders, 28, 36-39, 38t, 63
 Motor disorders/dysfunction, 31, 40-41
 Motor vehicle accidents/violations, 20, 52, 120
 advice and cautions about, 125, 126t
 MPH. See *Methylphenidate*.
 MRI (magnetic resonance imaging), 16, 31
 Multi-Modal Therapy of ADHD (MTA) trial, 63
 Multidimensional Anxiety Scale for Children, 35
 Multiple sclerosis, 32
 Myths about ADHD, 9-12
 National Attention-Deficit Disorders Association, 56
 National Guard, participation in, 55
 National Institute for Mental Health (web site), 56
 National Parent Information Network, 100t

- National Resource Center for ADHD (web site), 57
 Nausea, bupropion and, 90
 Neurologic exam, 25, 26
 Nicotine exposure, 15
 Non-FDA-approved medications, 88-91.
 See also *Medications for ADHD*.
 Nonstimulant medications, 86-88
 Nootropic medications, 115
 Norepinephrine neurotransmitter systems, 16, 63
 atomoxetine and, 86
 stimulant medications and, 63
 tricyclic antidepressants and, 89
 Norpramin (desipramine), 89
 Nortriptyline (Pamelor), 89
 Nystatin, 114
 NYU Child Study Center, 100t
- Obsessive-compulsive disorder (OCD), 40
 Obstructive sleep apnea, 32
 ODD. See *Oppositional defiant disorder*.
 Oligoantigenic (oligoallergenic) diet, 112
 Omega-3 fatty acids, 113
1-2-3 Magic: Effective Discipline for Children (Phelan), 100t
 Oppositional defiant disorder (ODD), 35-36, 36t
 OROS-methylphenidate (Concerta), 66t, 71-72.
 See also *Methylphenidate*.
 abuse potential (reduced), 64, 128
 approval for adults, 72
 blood concentration over time, 60
 contraindications, 71
 dosing and pharmacokinetics, 64, 66t, 77, 91
 duration of action, 77
 efficacy, 71-72, 72, 73
 Osmotic pump (OROS-methylphenidate), 71
 Outcomes, long-term, 20-21
 Overfocussing, stimulant medications and, 76, 80
- Pamelor (nortriptyline), 89
 PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections), 40
 Panic attacks, 39
 Parent-Child Interaction Therapy (PCIT), 100-103, 101t-102t
 Parent Global Perceptions questionnaire, 65
 Parent Management Training Oregon Model (PMTO), 102t
Parenting the Strong-Willed Child (Forehand and Long), 100t
 Parents. See also *Rating scales*.
 communication with teachers, 107
 disagreement with reports of, 17-18, 26-27, 27t
 parent-training programs, 99-105, 101t-103t
 books and resources on, 100t
 Parents, parent-training programs (continued)
 elements of, 103-105, 104t
 as source of information for diagnosis/monitoring, 17-18, 23-25, 92
 Passionflower, 114
 Patient
 destigmatizing ADHD in communication with, 49, 55-56
 education for, 47, 49, 55-56
 feedback for, 46, 47-49, 107, 108t
 involvement in management plan/process, 46-47, 50-51, 62
 self-management, support for, 45, 46-47
 support groups for, 56
 Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS), 40
 Pemoline, 59
 Permanent Product Measure of Performance (PERMP), 83, 84-85
 PERMP (Permanent Product Measure of Performance), 83, 84-85
 Pervasive developmental disorders, 28, 32
 Phobias, 39
 Physical conditions, comorbid with ADHD, 41
 Physical exam, 25, 26, 32
 Piracetam, 115
 Pittsburgh Side Effects-Rating Scale, 146-147
 Play therapy, 99
 Police department, career in, 55
 Positive attention and reinforcement, 103-105, 104t
 Positive Parenting Program (Triple P), 102t-103t
 Positron emission tomography, 16
 Posttraumatic stress disorder (PTSD), 39
 Prefrontal cortex, 16, 63
 Premature birth, ADHD and, 15
 Preservatives, food, 111-112
 Prevalence of ADHD, 16-20, 18, 119
 difficulties in determining, 16-19
 DSM changes and, 18, 18
 gender and, 12, 19
 race/ethnicity and, 19
 sampling and, 18-19
 substance abuse disorders and, 119-120
 variance in, 19
 Prevalence of comorbid conditions, 33
 Provigil (modafinil), 90-91
 Psychoeducational counseling, 27t
 Psychoeducational tests, 34
 Psychosocial treatments, 99-110
 adolescent and adult behavioral interventions, 107-109
 communication/daily report card (DRC), 107, 108t
 parent-training programs, 99-105, 100t, 101t-103t
 school services, 105-107
 Psychotic symptoms, stimulant medications and, 76, 80

Punishment, in behavior-modification training, 103, 104t, 105
Pycnogenol, 114

Questionnaires. See *Rating scales*.

Race/ethnicity, ADHD prevalence and, 19

Rating scales, 30-32, 30t, 32t, 91-92, 134-147
adult, for retrospective symptoms, 32
Adult Self-Rating Scale (ASRS), 31-32
Barkley version, 31
Brown Adult ADD Scale, 32t
Brown Adults Attention Disorder Scale (BAADS), 32
communication and, 49
for comorbid conditions, 35
Conners Adolescent ADD Scale, 32t
Conners Adolescent ADHD scale, 30t, 31
Conners Adult ADD Scale, 32t
Conners Adult ADHD Rating Scale (CAARS), 31
Conners Teacher and Parent Rating Scales, Revised, 30, 30t
core symptom monitoring with, 91-94
in diagnosis, 25, 26, 91
DSM-IV-based
for adults, 31-32, 32t
for children and adolescents, 30-31, 30t
DuPaul Parent and Teacher Rating Scales, 30, 30t
Parent Global Perceptions questionnaire, 65
Pittsburgh Side Effects-Rating Scale, 146-147
SKAMP, 31
SNAP-IV, 30, 30t, 31
specific medication assessments with
dexamphetamine, 65, 67t, 68t
lisdexamphetamine, 83-86, 84-85, 87
methylphenidate, 65, 67t, 68t, 69-75, 70, 71, 74, 75
mixed amphetamine salts, 81, 82
Vanderbilt Parent-Assessment Scale, 30, 31, 92, 134-137
Vanderbilt Parent-Assessment Scale Follow-up, 138-139
Vanderbilt Teacher-Assessment, 30, 92, 140-143
Vanderbilt Teacher-Assessment Follow-up, 144-145

Reading disabilities, 33-34

Rehabilitation Act (504), 105

Reinforcement, in behavior-modification training, 103-105, 104t

Resources
ADHD web sites, 56-57
on parent training, 100t

Rewards, in behavior-modification training, 103-105, 104t

Risk-taking behaviors, 52, 122

Ritalin, Ritalin LA, Ritalin SR, 59, 66t, 69. See also *Methylphenidate*.
dosing and pharmacokinetics, 66t, 77
duration of action, 69, 77
efficacy, 70-71, 71

Rule violation
in conduct disorder, 37t
punishments for, 104t, 105

Salicylate compounds, avoiding, 111-112

Scales. See *Rating scales*.

Schizophrenia, childhood, 28

School services, 105-107. See also *Education*.

Screening for substance-use disorders, 122-124, 123

Sedation
 α -adrenergic medications and, 90
tricyclic antidepressants and, 89

Seizure disorders, 32, 63

Seizures
bupropion and, 90
dextroamphetamine and, 63
methylphenidate and, 63

Self-management, support for, 45, 46-47

Sensory integration, 115-116

Separation anxiety disorder (SAD), 39-40

Sickle cell anemia, 32

Single-photon emission computed tomography. See *SPECT*.

SKAMP rating scale, 31
lisdexamphetamine assessment with, 83, 84-85
methylphenidate assessment with, 73-75, 74, 75

Sleep disorders, 32
modafinil for, 90

Sleep disturbance
amphetamines and, 81, 86
atomoxetine and, 86
clonidine as sleep aid, 90
history of, 75-76
methylphenidate and, 75-76

Smoking. See *Nicotine exposure*.

SNAP-IV rating scale, 30, 30t, 31
in evaluation of methylphenidate, 72

Social-skills training, 99, 106-107

Soft neurologic signs, 10, 31

Somnolence, atomoxetine and, 86

SPECT (single-photon emission computed tomography), 16, 31

Speech assessment, 105-106

Stevens-Johnson syndrome, 90

Still, George, 10, 11

Stimulant medications, 59-88, 66t. See also *Medications for ADHD*:
specific medications.
abuse potential, lower, 64
amphetamines, 66t, 79-86
cardiac side effects, 78-79, 128t
coverage needs/daily activities and, 94
dexmethylphenidate, 66t, 73-74

Stimulant medications (*continued*)

- differences in, 63
 - diversion of, 94, 125-128
 - guidelines for avoidance and recognition of, 127-128, 128t
 - red flags and precautions for, 128t
 - dosing and pharmacokinetics, 66t, 76-78, 77, 91
 - efficacy, 60-63, 61
 - core symptoms and, 62, 91-94
 - of second medication after non-response to first, 60, 65-69, 67t, 68t
 - short-term vs long-term, 62-63
 - history of, 59
 - individual differences in response, 74-75, 76, 80
 - lisdexamfetamine, 66t, 81-86
 - in medication algorithms, 92, 93
 - methylphenidate, *II*, 65-79, 66t
 - response rates, 60-61, 61
 - safety, 61-62, 63, 78-79
 - selection of, 64, 91
 - substance-use disorders and, 126t-127t
 - titration, 64-65, 92
- Strattera (atomoxetine), 86-88, 92
- Strictures of the GI tract, 71
- Students With Disabilities Office, registering with, 54-55
- Substance abuse. See *Substance-use disorders*.
- Substance-use disorders (SUDs), 62, 119-132
- abuse of stimulant medications, 64
 - ADHD medications and, 126t-127t
 - algorithm for assessment and treatment, 123
 - bipolar disorder and, 121
 - conduct disorder (CD) and, 36, 120, 121
 - counseling for, 109
 - diagnosis of ADHD in, 124
 - diversion of stimulant medications, 125-128
 - guidelines for avoidance and recognition of, 127-128, 128t
 - red flags and precautions for, 128t
 - DSM-IV* criteria, 126t-127t
 - feigning of ADHD to get medications, 124
 - level of use/abuse, 126t-127t
 - overlap with ADHD, 20, 119-121
 - predictive factors for, 121-122
 - prevalence of, 119
 - coexisting with ADHD, 20, 119-120
 - prognosis for, ADHD and, 121-122
 - risk of, in adolescents, 52
 - screening and assessment, 122-124, 123
 - treatment of, 123, 124-125, 126t-127t
- “Subsyndromal” patients, 29-30
- Subtypes of ADHD, *II*, 12, 23, 27-28
- combined types, 28
 - core symptoms of, 24t

Subtypes of ADHD (*continued*)

- predominantly hyperactive/impulsive type, 12, 24t, 28
 - predominantly inattentive type, 12, 19, 24t, 27
- Sudden cardiac death (SCD), 78, 79
- Sugar-restriction diet, 112-113
- Suicidal ideation, atomoxetine and, 86
- Supplements, dietary, 113-114
- Support groups, 56
- Swallowing, difficulty with, 65, 73, 81, 83
- Swanson, Kotin, Atkins, M-Flynn, and Pelham Department rating scale. See *SKAMP rating scale*.
- Symptoms of ADHD
- compensation for, 28, 45, 50, 94
 - continuing into adulthood, 9, 12, 20
 - core, 24t, 29
 - monitoring of, 91-94
 - duration of, diagnosis and, 27t, 28
 - mimicked by other conditions, 32
- Teachers. See also *Rating scales*.
- communication with parents, 107
 - disagreement with parents, 17-18, 26-27, 27t
 - feedback from, 47-49
 - involvement in management plan, 45
 - as source of information for diagnosis/monitoring, 17-18, 23-25, 92
- Tenex (guanfacine), 89-90
- Testing accommodations, 55, 105-106
- Thyroid hormone, unresponsiveness to, 41
- Tics and tic disorders, 40
- amphetamines and, 80
 - methylphenidate and, 76
- Timeline of ADHD history, *II*
- Tobacco use, 119
- Tofranil (imipramine), 89
- Token system of rewards, 104-105
- Tourette’s disorder, 40. See also *Tics and tic disorders*.
- Trauma
- brain, ADHD and, 15-16
 - closed head injuries, 32, 41
- Treatment of ADHD
- alternative treatments, 111-118
 - alternative medications, 114-115
 - communicating with patient about, 116
 - dietary supplements, 113-114
 - diets, 111-113
 - exercises and training, 115-116
 - behavior modification, 99-105, 100t, 101t-103t, 107-109
 - chronic-illness approach, 45-57, 46t
 - community/health care resources, 45-46, 46t
 - feedback in, 47-49, 107, 108t

Treatment of ADHD (*continued*)
goals for, 47
management plan, 46-49, 48. See also *Management plan for ADHD*.
for adolescents, 50-55, 53t
for adults, 55-57
medications, 59-97. See also *Medications for ADHD*;
and specific medications.
alternative, 114-115
FDA-approved, 59-88, 66t
management of, 91-95
methylphenidate, 65-79
non-FDA-approved, 88-91
nonstimulant, 86-88
stimulant, 59-88, 66t
substance-use disorders and, 126t-127t
monitoring and follow-up, 46, 47, 91-94
psychosocial treatments, 99-110
adolescent and adult behavioral interventions, 107-109
communication/daily report card (DRC), 107, 108t
parent-training programs, 99-105, 100t, 101t-103t
school services, 105-107
self-management support, 45
written treatment plan, 47, 48
Treatment of substance-use disorders, 123, 124-125, 126t-127t
Tricyclic antidepressants, 59, 89
Triple P (Positive Parenting Program), 102t-103t
Tutoring, 99
Twin studies, 15

Valerian root, 114
Vanderbilt Rating Scales, 30-31, 92
Parent-Assessment Scale, 30, 31, 134-137
Parent-Assessment Scale Follow-up, 138-139
Teacher-Assessment, 30, 140-143
Teacher-Assessment Follow-up, 144-145
Vitamins
megavitamins, 113
vitamin C, deficiency of, 112
Vyvanse. See *Lisdexamfetamine*.

Web sites
ADHD, 56-57, 100t
parent training, 100t
rating scales, 30t, 32t
Wechsler Adult Intelligence Scale (WAIS), 34
Wechsler Intelligence Scale for Children, 4th Edition (WISC-IV), 34
Weight loss
amphetamines and, 81
major depression and, 38t
methylphenidate and, 75

Wellbutrin (bupropion), 90
Wender, Paul, 32
Whites (Caucasians), ADHD prevalence among, 19
Wilson's disease, 32
Woodcock Johnson III Test of Achievement, Revised, 34
Work. See *Employment*.

Yeast, eliminating from diet, 114-115
Youth Forum, 35

Zinc supplements, 114